Despite the uncertainty of a Donald Trump regime, Indian companies proved they have some inbuilt resilience.
Kiran Mazumdar-Shaw is a consistent presence on definitive global lists as one of the world’s most powerful women. As the Chairman and Managing Director of Biocon Limited, she is a trendsetter in the field of biotechnology in India. Here she takes time out for ‘India Global Business’ to give us an insight into her entrepreneurial drive and India’s own biotech journey.
The Indian pharmaceutical industry is holding on to a sliver of hope that it could become the supplier of choice for the US market.
Indian IT sector CEOs aren’t the only ones weighing every word uttered by US President Donald Trump for nuances and burning the midnight oil wondering how to maintain their lead in their largest market.
Against the backdrop of Indian Prime Minister Narendra Modi’s visit to the US in June, here is a very brief snapshot of some of the recent trends in the India US economic ties over the past few weeks.
Indian pharmaceutical industry has been and continues to be a great ambassador for India. Here are some of the companies that are flying the tricolour high globally in this sector.
India’s fourth-largest drug maker recently announced the acquisition of two US-based companies, InvaGen Pharmaceuticals and Exelan Pharmaceuticals, for $550 million.
Indian pharmaceutical major Dr Reddy’s Laboratories has launched Memantine Hydrochloride tablets in the US market following an approval from the United States Food & Drug Administration (USFDA).